NASDAQ:IKT Inhibikase Therapeutics (IKT) Stock Price, News & Analysis $1.87 0.00 (0.00%) Closing price 06/24/2026 04:00 PM EasternExtended Trading$1.86 -0.01 (-0.53%) As of 06/24/2026 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Inhibikase Therapeutics Stock (NASDAQ:IKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get IKT alerts:Sign Up Key Stats Today's Range$1.85▼$1.9250-Day Range$1.57▼$2.0652-Week Range$1.33▼$2.26Volume937,757 shsAverage Volume570,475 shsMarket Capitalization$246.90 millionP/E RatioN/ADividend YieldN/APrice Target$5.40Consensus RatingBuy Company Overview Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia. Read More Inhibikase Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks33rd Percentile Overall ScoreIKT MarketRank™: Inhibikase Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 62nd out of 86 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingBuy Consensus RatingInhibikase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.11, and is based on 4 strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialInhibikase Therapeutics has a consensus price target of $5.40, representing about 188.8% upside from its current price of $1.87.Amount of Analyst CoverageInhibikase Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Inhibikase Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Inhibikase Therapeutics are expected to decrease in the coming year, from ($0.40) to ($0.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibikase Therapeutics is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibikase Therapeutics is -4.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibikase Therapeutics has a P/B Ratio of 0.81. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.12% of the float of Inhibikase Therapeutics has been sold short.Short Interest Ratio / Days to CoverInhibikase Therapeutics has a short interest ratio ("days to cover") of 24.57, which indicates bearish sentiment.Change versus previous monthShort interest in Inhibikase Therapeutics has recently increased by 4.63%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInhibikase Therapeutics does not currently pay a dividend.Dividend GrowthInhibikase Therapeutics does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 2 people have searched for IKT on MarketBeat in the last 30 days. This is a decrease of -78% compared to the previous 30 days.MarketBeat Follows6 people have added Inhibikase Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders7.10% of the stock of Inhibikase Therapeutics is held by insiders.Percentage Held by Institutions3.81% of the stock of Inhibikase Therapeutics is held by institutions.Read more about Inhibikase Therapeutics' insider trading history. Receive IKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IKT Stock News HeadlinesLifeSci Capital Keeps Their Buy Rating on Inhibikase Therapeutics (IKT)May 17, 2026 | theglobeandmail.comAnalyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk FactorsMay 14, 2026 | tipranks.comSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of the profits are typically already gone. SpaceX insiders bought in at a $20 billion valuation - you're being offered entry at $1.75 trillion. But one small, publicly traded company sits directly in SpaceX's supply chain, still priced like Wall Street hasn't noticed. It powers critical infrastructure Musk's operation can't run without. Dylan Jovine is naming it today, free. | Behind the Markets (Ad)Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent ActivityMay 12, 2026 | globenewswire.comInhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial HypertensionMay 12, 2026 | tipranks.comInhibikase enrolls first patient in phase 3 PAH trialApril 14, 2026 | msn.comInhibikase grants stock options to five new employeesApril 8, 2026 | msn.comInhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial HypertensionApril 7, 2026 | globenewswire.comSee More Headlines IKT Stock Analysis - Frequently Asked Questions How have IKT shares performed this year? Inhibikase Therapeutics' stock was trading at $2.05 at the beginning of 2026. Since then, IKT stock has decreased by 8.8% and is now trading at $1.87. How were Inhibikase Therapeutics' earnings last quarter? Inhibikase Therapeutics, Inc. (NASDAQ:IKT) posted its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.10) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.10). When did Inhibikase Therapeutics' stock split? Inhibikase Therapeutics's stock reverse split on the morning of Friday, June 30th 2023.The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Inhibikase Therapeutics IPO? Inhibikase Therapeutics (IKT) raised $20 million in an initial public offering on Wednesday, December 23rd 2020. The company issued 1,800,000 shares at $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO. Who are Inhibikase Therapeutics' major shareholders? Inhibikase Therapeutics' top institutional investors include ADAR1 Capital Management LLC (5.00%), Kalehua Capital Management LLC (2.89%), Perceptive Advisors LLC (1.75%) and SummitTX Capital L.P. (1.15%). View institutional ownership trends. How do I buy shares of Inhibikase Therapeutics? Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inhibikase Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD) and Intel (INTC). Company Calendar Last Earnings5/12/2026Today6/24/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 IKT's financial health is in the Yellow zone, according to TradeSmith. IKT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Biological Products, Except Diagnostic Substances Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IKT Previous SymbolNYSE:IKT CIK1750149 WebN/A Phone(678) 392-3419FaxN/AEmployees6Year Founded2008Price Target and Rating Average Price Target for Inhibikase Therapeutics$5.40 High Price Target$8.00 Low Price Target$4.00 Potential Upside/Downside+188.8%Consensus RatingBuy Rating Score (0-4)3.11 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-41.31% Return on Assets-38.98% Debt Debt-to-Equity RatioN/A Current Ratio30.14 Quick Ratio30.14 Sales & Book Value Annual Sales$260 thousand Price / Sales949.60 Cash FlowN/A Price / Cash FlowN/A Book Value$2.30 per share Price / Book0.81Miscellaneous Outstanding Shares132,030,000Free Float122,659,000Market Cap$246.90 million OptionableN/A Beta0.92 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:IKT) was last updated on 6/25/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredTrump just signed itA recent policy development is drawing attention from income-focused investors. According to one analyst, c...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
